Renal Care Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Dialysis Equipment, Dialysis Consumables, Renal Care Drugs, Others), By Modality (Hemodialysis, Peritoneal Dialysis, Kidney Transplantation), By End-Users (Hospitals, Dialysis Centers, Home Care Settings, Speciality Clinics) and Region 2020-2031

Renal Care Market was valued at US$ 98.2 billion in 2024 and is projected to reach US$ 143.8 million by 2031 at a CAGR of 5.6% from 2025-2031. Moreover, the U.S. Market is projected to grow at 5.4% of CAGR over the forecast period. The market refers to the industry focused on the diagnosis, treatment, and management of kidney-related conditions such as chronic kidney disease (CKD), end-stage renal disease (ESRD), and acute kidney injury (AKI). It encompasses a wide range of services, technologies, devices, and pharmaceuticals, including dialysis systems, renal replacement therapies, transplantation services, and nephrology medications. This market serves both hospital-based and home-based patients, offering solutions to manage kidney function deterioration and improve patient outcomes. The renal care ecosystem includes medical equipment manufacturers, pharmaceutical companies, service providers, and healthcare institutions engaged in delivering kidney care across preventive, therapeutic, and palliative stages.

The market is witnessing sustained growth due to the rising prevalence of diabetes, hypertension, and an aging population—all of which contribute to a higher burden of kidney disease. Technological advancements in dialysis modalities, the growing adoption of home-based renal therapies, and increased healthcare access in emerging economies are accelerating market expansion. Governments and healthcare organizations worldwide are also investing in awareness campaigns and early detection programs, further boosting demand for renal care services. Moreover, innovations such as portable dialysis machines, wearable devices, and regenerative medicine techniques are reshaping patient management and convenience, making renal care more adaptive and patient-centered.

Facts & Figures

• According to CDC data, more than 35 million U.S. adults (over 1 in 7) have chronic kidney disease, though as many as 90% are unaware of their condition; each day, approximately 360 people begin dialysis or kidney transplantation in the U.S.
• Global epidemiological analysis indicates that in 2021, there were nearly 20 million new CKD cases worldwide (ASIR ~234 per 100,000 population) and approximately 674 million prevalent CKD cases (about 8.5% of global population), marking a ~92% rise since 1990.
• The International Society of Nephrology and associated studies report that over 850 million individuals globally live with kidney disease including CKD and AKI making it one of the most widespread chronic conditions worldwide.
• As per WHO-aligned studies, more than 2 million people currently receive dialysis or kidney transplants, yet this represents only around 10% of those in need; most treated patients are concentrated in high-income nations like the U.S., Japan, Germany, Brazil, and Italy.

Key Developments

• In January 2025, the U.S. Food and Drug Administration (FDA) approved MediBeacon’s Transdermal GFR (tGFR) System, which enables non-invasive, point-of-care assessment of kidney function without blood draws or urine collection. The technology uses a fluorescent tracer (Lumitrace) and a skin-mounted sensor to measure glomerular filtration rate (GFR) transdermally, simplifying kidney health diagnostics.
• In June 2025, Fresenius Medical Care secured FDA 510(k) clearance for the updated 5008X CAREsystem, enabling its commercialization of high?volume hemodiafiltration (HVHDF) across U.S. dialysis clinics. This system will be rolled out starting later in 2025, with broader deployment in 2026. Supported by evidence from the CONVINCE trial which demonstrated a 23% mortality reduction compared to standard hemodialysis this launch represents a key industry inflection point and introduces a new standard of care in U.S. dialysis therapy.
• In November 2024, SeaStar Medical’s Selective Cytopheretic Device (SCD) designed to modulate inflammation during chronic hemodialysis—received FDA Breakthrough Device Designation for use in ESRD patients. With over 480,000 U.S. dialysis patients currently affected by chronic inflammatory complications, analysts consider this the first device of its kind to target systemic inflammation in dialysis care. The designation fast-tracks development, offering patients early access and potentially improving long?term outcomes.

Renal Care Market Segmentation

Based on the product

• Dialysis Equipment
• Hemodialysis Machines
• Peritoneal Dialysis Machines
• Dialysis Consumables
  • Dialyzers
  • Dialysate
  • Catheters
  • Bloodlines
• Renal Care Drugs
  • Erythropoietin Stimulating Agents
  • Phosphate Binders
  • Iron Supplements
  • Diuretics
• Others
  • Kidney Stone Management Devices
  • Renal Stents

Among the product segments of the renal care market, dialysis equipment segment particularly hemodialysis machines is anticipated to lead, driven by the escalating global burden of end-stage renal disease (ESRD) and the rising demand for life-sustaining dialysis treatments. Hemodialysis machines are the cornerstone of renal replacement therapy for patients with ESRD, especially in hospital and in-center settings. With over 3.5 million people worldwide receiving dialysis treatment, according to estimates from the International Society of Nephrology, the need for reliable and technologically advanced hemodialysis machines is growing rapidly. These machines are continually evolving, integrating smart monitoring, automation, and patient customization features that enhance safety and therapeutic efficiency. The rising prevalence of diabetes and hypertension major causes of CKD combined with aging populations in both developed and developing nations, is further fueling this demand. Government health programs and reimbursement schemes are also supporting infrastructure expansion. Consequently, hemodialysis machines are positioned as the leading driver within the renal care product landscape.

Based on the modality

• Hemodialysis
• In-Center Hemodialysis
• Home Hemodialysis
• Peritoneal Dialysis
• Continuous Ambulatory Peritoneal Dialysis (CAPD)
• Automated Peritoneal Dialysis (APD)
• Kidney Transplantation

Among the various modalities in the renal care market, hemodialysis specifically in-center hemodialysis is anticipated to remain the leading segment, primarily driven by its widespread adoption, availability of skilled healthcare professionals, and robust clinical infrastructure. In-center hemodialysis continues to be the standard of care for patients with end-stage renal disease (ESRD) across most regions, especially in middle- and high-income countries. This modality allows for consistent, professionally monitored treatments, which is particularly crucial for patients with complex comorbidities. According to the United States Renal Data System (USRDS), over 60% of dialysis patients in the U.S. rely on in-center hemodialysis. The predictability of treatment schedules and lower risk of patient-managed errors further contribute to its dominance. Despite emerging trends favoring home-based options, the need for continuous supervision, infection control, and emergency care access makes in-center hemodialysis the preferred choice for a vast majority of ESRD patients globally, ensuring its sustained leadership in the market.

Based on the end-user

• Hospitals
• Dialysis Centers
• Home Care Settings
• Speciality Clinics

The dialysis centers are anticipated to lead among end-users, primarily due to their specialization, cost efficiency, and expanding global presence. Dialysis centers offer dedicated facilities exclusively for managing patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), ensuring high patient throughput, streamlined care, and access to skilled nephrology professionals. These centers are increasingly preferred for their ability to deliver consistent, high-quality hemodialysis and peritoneal dialysis treatments at a lower cost compared to hospitals. In countries like the United States, more than 70% of patients receiving dialysis are treated at outpatient dialysis centers, according to data from the Centers for Medicare & Medicaid Services (CMS). Global dialysis service providers such as Fresenius Medical Care and DaVita are continuously expanding their network of centers, especially in Asia and Latin America, to meet rising demand. The trend toward decentralized, specialized renal care combined with growing public-private investment—is cementing dialysis centers as the dominant end-user segment in this market.